Phreesia, Inc. · NYSE:PHR
Phreesia — Investor Presentation (September 2021)
19 slides from Phreesia's investor presentation, September 2021
Slide 1: Investor Presentation September 2021
Investor Presentation September 2021
Slide 2: Disclaimers and Forward-Looking Statements
DISCLAIMERS AND FORWARD-LOOKING STATEMENTS This presentation includes express or implied statements that are not historical facts and are considered forward- looking within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act. Forward-looking statements inv
Slide 3: Our Mission
OUR MISSION To create a better, more engaging healthcare experience 3
Slide 4: Phreesia is Patient Intake
~1,900 healthcare is Patient Intake provider organizations ~$2.0B patient payments processed in FY21 Who we are: Leading provider of comprehensive solutions that transform the healthcare experience by engaging patients in their care $149M revenue in FY21 What we do: Enable healthcare provider organi
Slide 5: Attractive Industry Tailwinds
ATTRACTIVE INDUSTRY TAILWINDS Wasteful Increasing Patient Increasing Shift to Value-Based Focus on Spending Responsibility Consumerism Care Models Personalized Healthcare Solutions • 1.2M intake staff • $586B out-of- • Demand for higher • Payment model • Need to directly represent $37B in pocket spe
Slide 6: Our Value Proposition and How We Make Money
OUR VALUE PROPOSITION AND HOW WE MAKE MONEY Providers Patients Life Sciences Companies • Simplified operations & enhanced • Improved patient experience • Targeted, direct digital marketing Value proposition staff efficiency • High patient usage • Improved brand conversion and • Improved cash flow an
Slide 7: Our End-to-End Patient Intake Solution
OUR END-TO-END PATIENT INTAKE SOLUTION Patients Use These: Staff Use These: AT HOME, ON THE GO, IN THE OFFICE IN THE OFFICE IN THE OFFICE IN THE OFFICE PhreesiaPad Mobile Arrivals Station Phreesia Dashboard Analytics Real-time Integration Electronic Practice Telehealth Practice Data Payment Medical
Slide 8: The Phreesia Platform
THE PHREESIA PLATFORM Registration Revenue Cycle Appointments Patient Activation Clinical Support Branded patient Intake Workflows Insurance verification Online appointment requests COVID-19 Screening Module announcements Appointments queue COVID-19 Vaccine Consent management POS payments Digital Pa
Slide 9: Phreesia Named the 2021 Best in KLAS for Patient Intake Management
Phreesia Named the 2021 Best in KLAS for Patient Intake Management In its annual “Best in KLAS: Software and Services” report, KLAS named Phreesia the 2021 Best in KLAS for Patient Intake Management, based on survey data from provider groups on customer experience pillars, such as loyalty, value and
Slide 10: Our Current Addressable Market
OUR CURRENT ADDRESSABLE MARKET Consumer-Related Transaction Subscription-Based Revenue Life Sciences And Payment Processing Fees ~50K addressable provider clients1 $93B addressable out-of-pocket3 DTC point-of-care in United States in United States marketing spend4 ~1.3M individual providers2: ~1.0M
Slide 11: Scalable from Small Businesses to Large Enterprises
SCALABLE FROM SMALL BUSINESSES TO LARGE ENTERPRISES 25+ medical specialties of varying sizes ~40 life sciences brands Providers Life Sciences Physician groups Health systems Pharma manufacturers • Top 3 global pharma company • Top 3 global biotech company z • Top 5 diabetes pharma manufacturer • Top
Slide 12: Multiple Growth Opportunities
MULTIPLE GROWTH OPPORTUNITIES Grow footprint Cross-sell new Margin Partnerships and Land new clients within existing applications to expansion M&A clients existing clients through scale • Direct sales model • Additional providers • Proven ability to • New applications • Opportunistic • Acute care ma
Slide 13: Financial Overview
Financial Overview 13
Slide 14: Scalable and Predictable Sources of Revenue
SCALABLE AND PREDICTABLE SOURCES OF REVENUE REVENUE MODEL DRIVERS FY21 % REV Subscription and related • New provider clients services1 • Includes base package and add-on applications • Majority of fees charged per provider per month (PPPM) • Expansion within existing clients 46% • New products and a
Slide 15: Operating and Financial Highlights
OPERATING AND FINANCIAL HIGHLIGHTS Avg. Number of Avg. Provider Total Revenue ($M) Provider Clients Revenue Per Client Adj. EBITDA ($M) Provider Life Sciences +46% +19% +14% $51.0 1,987 20,222 $48.2 19,720 1,902 $35.0 1,668 17,357 $39.2 +35% $38.4 $28.9 $1.2 $0.1 $11.8 $9.8 +95% $6.1 -$11.0 Q2 FY21
Slide 16: Appendix
Appendix 16
Slide 17: Detailed Income Statement
DETAILED INCOME STATEMENT $M Fiscal year ended January 31 Three months ended July 31 FY 2020 FY 2021 Q2 2021 Q2 2022 Revenue: Subscription and related services $56.4 $69.0 $17.1 $22.9 Payment processing fees 46.5 49.9 11.8 16.3 Total provider revenues $102.9 $118.9 $29.0 $39.2 % Growt h 35.3% Life s
Slide 18: Adjusted EBITDA Reconciliation
ADJUSTED EBITDA RECONCILIATION1 $M Fiscal year ended January 31 Three months ended July 31 FY 2020 FY 2021 Q2 2021 Q2 2022 Reconciliation to Adjusted EBITDA Net loss ($20.3) ($27.3) ($6.4) ($24.4) Interest expense (income), net 2.4 1.6 0.4 0.2 (Benefit) provision for income taxes 1.8 0.0 0.1 0.3 Dep
Slide 19: Watch the Video by Clicking Below
WATCH THE VIDEO BY CLICKING BELOW 19